- Home
- OGS vs SRRK Comparison
OGS vs SRRK Comparison
Compare OGS & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OGS | SRRK |
|---|---|---|
| Founded | 1906 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6B | 4.6B |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | OGS | SRRK |
|---|---|---|
| Price | $79.04 | $44.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 11 |
| Target Price | ★ $84.57 | $51.20 |
| AVG Volume (30 Days) | 361.2K | ★ 1.0M |
| Earning Date | 02-18-2026 | 02-26-2026 |
| Dividend Yield | ★ 3.47% | N/A |
| EPS Growth | ★ 11.73 | N/A |
| EPS | ★ 4.27 | N/A |
| Revenue | ★ $2,368,759,000.00 | N/A |
| Revenue This Year | $23.63 | N/A |
| Revenue Next Year | $4.58 | $20,029.43 |
| P/E Ratio | $18.07 | ★ N/A |
| Revenue Growth | ★ 15.06 | N/A |
| 52 Week Low | $68.19 | $22.71 |
| 52 Week High | $83.96 | $48.28 |
Technical Indicators
Market Signals| Indicator | OGS | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 56.46 | 52.70 |
| Support Level | $76.39 | $43.25 |
| Resistance Level | $79.37 | $48.28 |
| Average True Range (ATR) | 1.33 | 2.54 |
| MACD | 0.23 | 0.01 |
| Stochastic Oscillator | 79.97 | 56.89 |
Price Performance
Historical ComparisonAbout OGS ONE Gas Inc.
ONE Gas Inc is a regulated natural gas utility company. It is involved in the distribution and sale of natural gas to residential, commercial, industrial, and transportation consumers through its network of pipelines and service lines. Almost all of the company's revenue is derived from natural gas sales in the states of Oklahoma, Kansas, and Texas. The company controls considerable market shares in Oklahoma and Kansas.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.